Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir

1 Jan 2022

Abstract excerpt

This review considers antiviral nucleoside analog drugs, including ribavirin, favipiravir, and molnupiravir, which induce genome error catastrophe in SARS-CoV or SARS-CoV-2 via lethal mutagenesis as a mode of action. In vitro data indicate that molnupiravir may be 100 times more potent as an antiviral agent than ribavirin or favipiravir. Molnupiravir has recently demonstrated efficacy in a phase 3 clinical trial....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Plant Virus Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35023215
DOI: 10.1002/em.22471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravirPMID 35023215Read ↗

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis - the special case of molnupiravirSemantic proximity Read ↗

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravirSemantic proximity Read ↗

β- d - N 4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian CellsSemantic proximity Read ↗

The genetic toxicity effects of lamivudine and stavudine antiretroviral agents.Semantic proximity Read ↗

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral ActivitySemantic proximity Read ↗

Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugsSemantic proximity Read ↗

Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapiesSemantic proximity Read ↗

Disentangling Origin of the SARS-CoV-2 FCS from Emerging Risk: Convergent Biorisk Hazards via DNA-Repair Mechanisms, RNA Oncogenic Viruses, and Possible Covert Laboratory ExperimentsSemantic proximity Read ↗

Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin.Semantic proximity Read ↗

HSV-1 Delta ribonucleotide reductase as a Model to Investigate Molnupiravir-Induced MutagenesisSemantic proximity Read ↗

Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 TreatmentSemantic proximity Read ↗

Evolutionary safety of death by mutagenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.